Loading...

SUNPHARMA Sun Pharmaceuticals Industries Ltd Product Launches Announcement

Sn P

SNPH

Sun Pharmaceuticals Industries Ltd

(SUNPHARMA)

2023 Announcement

Show Summary

Summary

Financial Results

Investor Call Recording

Settlement Agreement

Successful Study Results

Transfer Deed Window

New Subsidiary in China

Newspaper Publication

Investor Presentation

Compliance Certificate

LEQSELVI Launch

Settlement Announced

Investor Meeting

FDA Halol Update

Management Change

Clinical Trial Results

Checkpoint Acquisition

Compliance Report

Q4 FY25 Earnings Call

Investment Update

Investor Call Recording

Secretarial Auditor Appoint...

Directorate Changes

Investor Meeting Schedule

FDA Approval Announcement

Fourth Quarter Results

Brand Campaign Launch

CFO Change Announcement

New Product Launch

Confirmation Certificate

Injunction Vacated

New Drug Launch

Change in Directorate

Lyndra Operations Cease

Acquisition Complete

Acquisition Update

Checkpoint Acquisition

Investor Presentation

Top Sustainability Ranking

Investor Meeting

Q3 FY25 Earnings

Regulatory Penalty Imposed

Regulatory Order

Investor Meeting Scheduled

Trial Enrollment Success

Investor Meeting Schedule

Sustainability Report

New COO Appointment

Investor Call Audio

Earnings Call Scheduled

Antibe Acquisition

Compliance Certificate

Sale of Subsidiary

NCLT Meeting Notice

Regulatory Order

Regulatory Order

Regulatory Order Update

NCLT Meeting Announcement

Investor Presentation

Regulatory Orders Issued

Investor Meeting Scheduled

Regulatory Order

Investor Meet Schedule

Regulatory Order

Regulatory Penalty

Earnings Call Transcript

Court Injunction Granted

Investor Call Recording

WINLEVI Study Results

LEQSELVI Update

Q2 Earnings Announcement

Regulatory Update

Regulatory Compliance

Regulatory Order

Fibromun Agreement

Investor Presentation

Clinical Data Presentation

Volume Increase Clarification

Regulatory Penalty

Investor Meetings

Regulatory Order

FDA Fast Track Approval

Regulatory Order

Regulatory Order

Regulatory Order

Regulatory Penalty

Regulatory Orders

Regulatory Order

Regulatory Order

Regulatory Order

Investor Meeting Scheduled

ESG Overview Update

Regulatory Penalty

Regulatory Order

New Product Launch

Stake Acquisition

Analyst Meeting Announced

Meeting Schedule

Investor Call Recording

FDA Approval for LEQSELVI

Warning Letter Disclosure

Earnings Announcement

Newspaper Publication

Regulatory Order

Regulatory Order

Investor Presentation

Certificate Submission

Newspaper Advertisement

Announcement Summary

Regulatory Order

Regulatory Order

AGM Announcement

Merger Completion

Positive Results on GL0034 ...

Pharma Licensing Agreement

Clinical Trial Data Announc...

Regulatory Order

Regulatory Order

Sun Pharma Marketing Author...

Results of Phase III Trial

Acquisition of IFQM

Investor Meeting

Earnings Call Transcript

Compliance Report Submission

Analyst/Investor Meet

Merger Approval

Regulatory Order

Valstar Acquisition

Regulatory Order

Regulatory Order

Compliance Certificate Filing

Regulatory Order

Regulatory Order

Compliance Certificate

FDA Inspection Outcome

Regulatory Penalty Imposed

Newspaper Publication

Compliance Certificate Subm...

Management Change

Retirement of Director

Volume Movement Response

Regulatory Orders

Regulatory Order

Penalty Imposed

Sun Pharmaceutical Winlevi(...

Investor Presentation

Analyst Meeting

Penalty Imposed

Shareholder Satisfaction Su...

Regulatory Order

S&P Global Yearbook Inclusion

Subsidiary Incorporation

Incorporation of Subsidiary

Investor Conferences

Earnings Call Audio Recording

Financial Results Q3FY24

Merger Agreement

Marketing Agreement

Earnings Call Announcement

Regulatory Action

Confirmation Certificate Su...

Investor Presentation

Order from Statutory Author...

Product Inclusion

Acquisition Update

Management Changes

Licensing Agreement

Closure of Sun Pharma ESOP ...

Response to Query

Meetings Schedule

Financial Results Announcement

Financial Results and Schem...

Licensing Agreement

Sustainability Report

CEQUA Phase 4 Data

Certificate Submission

US FDA Filing Acceptance

Acquisition of Minority Stake

Investor Meetings

Licensing Agreement

Submission of ESG Overview

Sun Pharma AGM Speech

Schedule of Analyst/Investo...

Analyst/Investor Meet

Management Rights

Financial Statements

Meeting Schedule

Financial Statements

Financial Statements

Earnings Guidance

Financial Statements

Debt-Equity Swaps

Annual General Meeting

Public Presentation

New Product Launches

Conference Call Transcript

Meeting Schedule Disclosure

New Product Launches

Analyst/Institutional Meet

Financial Results

Disclosure of Related Party...

Financial Results

Regulatory Compliance

External Links:

Data:

Sun Pharmaceutical Industries Ltd. announces that their specialty product ILUMETRI has been included in category B of Chinas National Reimbursement Drug List, effective from January 1, 2024.

AI Assistant

Sun Pharmaceuticals Industries Ltd

2023

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.